IL6 and breast carcinoma: Interestingly, BZA exhibited preclinical efficacy against HR-breast cancer, which was later attributed to its ability to bind the D1 domain of the GP130 receptor and subsequently disrupt IL-6/IL-6R/GP130 signaling [32,68].